![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/07/31/2921918/34858/en/Vaccinex-Reports-Positive-Data-for-SIGNAL-AD-Phase-1b-2-trial-of-Pepinemab-in-Alzheimer-s-Disease.html
https://www.globenewswire.com/news-release/2024/07/17/2914515/34858/en/Vaccinex-to-report-topline-data-for-SIGNAL-AD-Phase-1b-2-trial-of-Pepinemab-in-Alzheimer-s-Disease-at-the-Alzheimer-s-Association-International-Conference-Philadelphia-July-31-2024.html
https://www.globenewswire.com/news-release/2024/06/06/2894654/34858/en/Vaccinex-Reports-Completion-of-Last-Patient-Visit-in-Randomized-SIGNAL-AD-Phase-1b-2-Study-of-Pepinemab-Treatment-for-Alzheimer-s-Disease.html
https://www.globenewswire.com/news-release/2024/05/15/2883005/34858/en/Vaccinex-Reports-First-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2024/04/02/2855965/34858/en/Vaccinex-Reports-2023-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2024/03/27/2853151/34858/en/Vaccinex-Inc-Announces-1-5-Million-Registered-Direct-Offering-and-Concurrent-Private-Placement-Priced-At-the-Market-Under-Nasdaq-Rules.html
https://www.globenewswire.com//news-release/2024/02/21/2832705/34858/en/Vaccinex-Announces-Multiple-New-Agreements-for-Access-to-ActivMAb-Antigen-Virus-Technology.html
https://www.globenewswire.com//news-release/2024/02/15/2829923/34858/en/Vaccinex-Inc-Announces-Reverse-Stock-Split.html
https://www.globenewswire.com//news-release/2024/02/07/2825160/34858/en/Vaccinex-Announces-Pricing-of-3-7-Million-PIPE-Financing.html
https://www.globenewswire.com//news-release/2023/12/04/2789961/34858/en/Nasdaq-Grants-Vaccinex-Extension-Until-March-4-2024-to-Regain-Compliance-with-Listing-Rule.html